חוב כולל להון Sunshine Biopharma, Inc. (SBFM)

Sunshine Biopharma (SBFM) possesses authority in creating targeted agents against tumors and viruses. The quotes provided below demonstrate a debt-to-equity ratio of 0.02. The business relies on promising mRNA technologies for liver therapy and the development of oral medications, counting on future license sales to industry behemoths to scale its innovations.

When constructing a long-term portfolio, it is critical to evaluate financial leverage to eliminate the risk of bankruptcy during market shocks. This indicator measures the proportion of borrowed funds within the asset structure relative to equity, which for Sunshine Biopharma (SBFM) determines the ability to fund KAb-201 development and patent protection without critical dependence on creditors, reflecting this through the total debt-to-equity ratio.